Evaluation of DNA topoisomerase IIα expression provides independent prognostic information in non-Hodgkin's lymphomas

Histopathology

Volumn 38, Issue 1, 2001, Pages 45-53

  Korkolopoulou, P ^a,b   Angelopoulou, M ^a   Siakantari, M ^a   Mitropoulos, F ^a   Vassilakopoulos, T ^a   Zorzos, H ^a   Rassidakis, G ^a   Androulaki, A ^a   Patsouris, E ^a   Kittas, C ^a   Davaris, P ^a   Pangalis, G A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Immunohistochemistry; Non Hodgkin' s lymphoma; Survival; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); FORMALDEHYDE; MONOCLONAL ANTIBODY KI 67; PARAFFIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KI-67 ANTIGEN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0035150386     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2001.01036.x     Document Type: Article

References (35)

1. Alternative (non p-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphomas
2. DNA topoisomerase I and II in cancer chemotherapy: Update and perspectives
3. Structure and function of type II DNA topoisomerases
4. Catalytic function of DNA topoisomerase II
5. Harnessing the dark side of enzyme mechanism
6. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase IL
7. Transfection of human topoisomerase IIα into etoposide-resistant cells: Transient increase in sensitivity followed by down-regulation of the endogenous gene
8. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells
9. Proliferation- and cell cycle-dependent differences in expression of the 170 kDa and 180 kDa forms of topoisomerase II in NIH-3T3 cells
10. Expression of the 170 kDa and 180 kDa isoforms of DNA topoisomerase II in resting and proliferating human lymphocytes
11. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia
12. A clinical staging system for chronic lymphocytic leukemia: Prognostic significance
13. A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group
14. Lymphoma classification: The gap between biology and clinical management is closing
15. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
16. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas
17. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
18. Immunohistochemical detection of DNA topoisomerase IIα, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer
19. The distribitution and expression of the two isoforms of DNA topisomerase II in normal and neoplastic human tissues
20. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIα
21. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase IIα in human epithelial ovarian carcinoma and germ cell tumor
22. Human DNA topoisomerase IIalpha: A new marker of cell proliferation in invasive breast cancer
23. Immunohistochemical staining for DNA topoisomerase IIα in Hodgkin's disease
24. Immunohistochemical study of DNA topoisomerase II in human gastric disorders
25. The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphomas
26. Prognostic significance of the Ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial
27. Prognostic implications of proliferating cell nuclear antigen (PCNA). AgNORs and p53 in non-Hodgkin's lymphomas
28. Review: Assessment of cell proliferation in histological material
29. Prognostic significance of the expression of topoisomerase-IIα in diffuse large cell lymphomas
30. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression
31. Quantitative and qualitative aspects of topoisomerase I and IIα and IIβ in untreated and platinum/cyclophosphamide-treated malignant ovarian tumors
32. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
33. DNA topoisomerase IIα and -β expression in human ovarian cancer
34. Prognostic relevance of apoptotic cell death in non-Hodgkin']s lymphomas: A multivariate survival analysis including Ki-67 and p53 oncoprotein expression